HIK.L
HIK.L
GB00B0LCW083
HIKMA PHARMACEUTICALS PLC ORD S
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 80/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±28.3% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.7x).

Beta (Market Relation)
0.65x
Defensive
Volatility (5Y p.a.)
28.3% p.a.
5-Year Horizon
Max Drawdown (5Y)
-51.9%
5-Year Horizon
Sharpe Ratio
-0.34
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — -12.5%
3 Years 27.7% -49.1% -0.35 -7.3%
5 Years 28.3% -51.9% -0.34 -7.2%
10 Years 31.2% -62.8% -0.15 -2.2%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (28.3% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -62.8% in the extended horizon.

Corporate Governance & ISS Scores

Shareholder rights, board structure and audit safety (Scale 1 = Low Risk, 10 = High Risk)
Overall Governance Risk
3 ISS Score: 3 / 10
Audit Risk
6 ISS Score: 6 / 10
Board Risk
4 ISS Score: 4 / 10
Short Ratio
-
ende